|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS).
|
30940668 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since high serum TgAb levels may also affect the fine needle aspiration washout Tg levels from suspicious lymph nodes of DTC patients, it is important to use caution when interpreting the washout Tg levels in patients who are positive for TgAb.
|
30396251 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Along with the detection of serum thyroglobulin and anatomic imaging modalities, such as ultrasound and computer tomography, radionuclide molecular imaging plays a vital role in the evaluation of RR-DTC.
|
29650270 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients.
|
29854387 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of Serum TSH and Anti-Thyroglobulin Antibody Levels on Lymph Node Fine-Needle Aspiration Thyroglobulin Measurements in Differentiated Thyroid Cancer Patients.
|
29234622 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified biomarkers associated with poor prognosis in DTC, including elevated baseline VEGFA and thyroglobulin and the presence of <i>RAS</i> mutations.
|
31558473 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The <i>BRAF</i> status and stimulated thyroglobulin levels at ablation time improve the ATA risk stratification of differentiated thyroid cancer; therefore, even A-hTg could be included in risk classification factors.
|
31093278 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thyroglobulin measurement in the management of patients with differentiated thyroid cancer.
|
29546779 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we show that MK can potentially be used as a surrogate biomarker for predicting DTC metastases when Tg is not suitable due to TgAb positivity.
|
28240744 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of the work was to investigate the relationship between thyroglobulin doubling time (TgDT) as a marker of speed of response to <sup>131</sup>I-therapy and the differentiated thyroid cancer (DTC) recurrence rate, DTC specific mortality rate, and relative survival rate in a DTC population followed over a long period of time after <sup>131</sup>I-therapy.
|
29136675 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer.
|
28723762 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer.
|
28509618 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this work is to evaluate a new health technology to assay thyroglobulin in patients with differentiated thyroid cancer to improve its service from an organizational point of view, by planning new and appropriate training activities, ensuring proper use of resources and satisfying the needs of different users.
|
31277572 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to determine if preoperative serum thyroglobulin (Tg) level could predict initial DM in DTC.
|
29209067 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic DTC discovered before radioiodine had higher thyroglobulin and received a higher radioiodine total activity and number of treatments.
|
29899030 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of Postoperative Stimulated Thyroglobulin as Prognostic Factor for Differentiated Thyroid Cancer in Children and Adolescents.
|
28292215 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Currently, the most valuable role FDG-PET/CT exists in the work-up of patients with differentiated thyroid cancer status post thyroidectomy who present with increasing thyroglobulin levels and a negative (131)I whole-body scan.
|
21272686 |
2011 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the diagnostic performance of cytology (fine-needle aspiration cytology [FNAC]), thyroglobulin (fine-needle aspiration thyroglobulin [FNA-Tg]), and combination of them in the washout of fine-needle aspiration for those patients who have suspicious metastatic lymph nodes of differentiated thyroid cancer.
|
31702649 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We compared three methods of blood collection and RNA extraction, and quantified Tg mRNA (by real time RT-PCR) in the peripheral blood of a) probands without thyroid disease (n=42), patients with b) thyroid autonomy (n=15), c) Graves' disease (n=22), d) euthyroid goiter (n=6), and in DTC-patients after thyroidectomy and radioiodine therapy e) with (n=16) and f) without (n=37) metastasis.
|
12444888 |
2002 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predictive value for excellent response to initial therapy in differentiated thyroid cancer: preablation-stimulated thyroglobulin better than the TNM stage.
|
29557849 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the usefulness of integrin imaging with <sup>99m</sup>Tc-PEG<sub>4</sub>-E[PEG<sub>4</sub>-c(RGDfK)]<sub>2</sub> (<sup>99m</sup>Tc-3PRGD2) single photon emission computed tomography (SPECT)/computed tomography (CT) in detecting recurrent disease in patients with differentiated thyroid cancer (DTC), negative radioiodine whole-body scan (WBS) and high serum thyroglobulin (Tg).
|
29323252 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer.
|
28493284 |
2017 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the accuracy of 18F-FDG-PET/CT for detection of recurrent and/or metastatic diseases in differentiated thyroid cancer (DTC) patients with thyroglobulin elevation and negative iodine scintigraphy.
|
31117054 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
|
14588101 |
2003 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to determine the factors that influence long-term disease-specific survival and thyroglobulin levels in patients with DTC who have been previously treated with thyroidectomy and radioactive iodine (RAI) remnant ablation.
|
31425569 |
2019 |